Gardiquimod (diTFA)

• UNSPSC Description:

  Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10?μM[1][2].

• Target Antigen:

  HIV; Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/Gardiquimod_trifluoroacetate.html

• Purity:

  99.0

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)

• Smiles:

  OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.FC(C(O)=O)(F)F.FC(C(O)=O)(F)F

• Molecular Weight:

  541.44

• References & Citations:

  [1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29(6):907-18.|[2]Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7(5):381-8.|[3]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369(2):298-306.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1159840-61-5